€80.4m market cap
€2.04 last close
Based in Spain, ADL Bionatur Solutions provides contract manufacturing of fermentation-based biochem products and antibiotics, and develops and licenses its own portfolio of OTC and prescription animal health products, including probiotics and vaccines.
Investment summary
ADL Bionatur Solutions (ADL-BS) provides contract manufacturing (CMO) of fermentation-based products and services focused on the health, beauty and wellness sectors. It has established CMO/API (active pharmaceutical ingredient) business lines and its own proprietary development line of novel or innovative products. ADL will have 2,400m3 of total fermentation capacity available by Q419. While this operated at c 40% utilisation in much of 2018, given recent contract wins and the ramping up in 2019 of its two largest contracts (a six-year €146m flucosil-lactose deal and an arrangement with Amyris), ADL expects to have 100% of capacity committed by year end 2019. This should drive it to firmly positive company-wide EBITDA and profitability in 2019.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (fd) (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 12.8 | (10.4) | (12.7) | (251.65) | N/A | N/A |
| 2018A | 25.3 | (12.5) | (16.3) | (43.16) | N/A | N/A |
| 2019E | 60.8 | 6.1 | 1.8 | 4.53 | 45.0 | N/A |
| 2020E | 73.5 | 11.2 | 6.2 | 15.82 | 12.9 | 8.0 |
| Last updated on 23/07/2019 | ||||||
Industry outlook
We estimate the ADL unit’s solid pipeline of existing CMO contracts will contribute to company-wide generation of at least €60m in 2019 revenue (vs €25m in 2018). We measure ADL 2018 net debt at approximately €40.6m, including a €7.0m loan from its majority shareholder. In August 2019, ADL received €25m in debt financing, which should fully fund the firm’s business plan for the next four years.
Last updated on 23/07/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (€m) | 50.3 |
| Forecast gearing ratio (%) | 219 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Pilar de la Huerta | CEO |
Content on ADL Bionatur Solutions
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma